Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
<h4>Background and aims</h4>Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and carries risks of complications. Fibr...
Enregistré dans:
Auteurs principaux: | Shan Liu, Michaël Schwarzinger, Fabrice Carrat, Jeremy D Goldhaber-Fiebert |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/cee6a3f304084a5b9154e1af5ab1e793 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Chronic hepatitis C: future treatment
par: Wendt A, et autres
Publié: (2014) -
Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
par: Oana Irina Gavril, et autres
Publié: (2021) -
Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies
par: Mendes LC, et autres
Publié: (2018) -
Review of consensus interferon in the treatment of chronic hepatitis C
par: Th Witth&ouml;ft
Publié: (2008) -
Quality of life and adherence to treatment of patients with chronic viral hepatitis C
par: R. S. Mirkhaydarov, et autres
Publié: (2018)